These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 11464883)

  • 21. Disposition of WR-1065 in the liver of tumor-bearing rats following regional vs systemic administration of amifostine.
    Levi M; DeRemer SJ; Dou C; Ensminger WD; Smith DE
    Biopharm Drug Dispos; 2004 Jan; 25(1):27-35. PubMed ID: 14716750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of amifostine and its metabolites in patients.
    Korst AE; Eeltink CM; Vermorken JB; van der Vijgh WJ
    Eur J Cancer; 1997 Aug; 33(9):1425-9. PubMed ID: 9337685
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro cytoprotective activity of squalene on a bone marrow versus neuroblastoma model of cisplatin-induced toxicity. implications in cancer chemotherapy.
    Das B; Yeger H; Baruchel H; Freedman MH; Koren G; Baruchel S
    Eur J Cancer; 2003 Nov; 39(17):2556-65. PubMed ID: 14602142
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Carboplatin and paclitaxel in non-small cell lung cancer: the role of amifostine.
    Selvaggi G; Belani CP
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):51-60. PubMed ID: 10348261
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Short duration, high dose, alternating chemotherapy in metastatic neuroblastoma. (ENSG 3C induction regimen). The European Neuroblastoma Study Group.
    Pinkerton CR; Zucker JM; Hartmann O; Pritchard J; Broadbent V; Morris-Jones P; Breatnach F; Craft AE; Pearson AD; Wallendszus KR
    Br J Cancer; 1990 Aug; 62(2):319-23. PubMed ID: 2386751
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protection of normal tissues from the cytotoxic effects of chemotherapy by amifostine (Ethyol): clinical experiences.
    Capizzi RL
    Semin Oncol; 1994 Oct; 21(5 Suppl 11):8-15. PubMed ID: 7973776
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients.
    Lorusso D; Ferrandina G; Greggi S; Gadducci A; Pignata S; Tateo S; Biamonte R; Manzione L; Di Vagno G; Ferrau' F; Scambia G;
    Ann Oncol; 2003 Jul; 14(7):1086-93. PubMed ID: 12853351
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug resistance in human neuroblastoma cell lines correlates with clinical therapy.
    Keshelava N; Seeger RC; Reynolds CP
    Eur J Cancer; 1997 Oct; 33(12):2002-6. PubMed ID: 9516842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Amifostine for protection from antineoplastic drug toxicity.
    Foster-Nora JA; Siden R
    Am J Health Syst Pharm; 1997 Apr; 54(7):787-800. PubMed ID: 9099346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase I dose escalation of combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with neuroblastoma.
    Fernandez MC; Krailo MD; Gerbing RR; Matthay KK
    Cancer; 2000 Jun; 88(12):2838-44. PubMed ID: 10870069
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of amifostine on toxicity of CHOP in elderly patients with aggressive non-Hodgkin's lymphoma--a phase II study.
    Späth-Schwalbe E; Lange C; Genvresse I; Krüger L; Eucker J; Schweigert M; Sezer O; Budach V; Possinger K
    Anticancer Drugs; 2002 Apr; 13(4):395-403. PubMed ID: 11984085
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amifostine: potential for clinically useful cytoprotection.
    Budd GT; Lorenzi V; Ganapathi R; Adelstein D; Pelley R; Olencki T; McLain D; Bukowski RM
    Support Care Cancer; 1994 Nov; 2(6):380-4. PubMed ID: 7858931
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A pilot study of addition of amifostine to melphalan, carboplatin, etoposide, and cyclophosphamide with autologous hematopoietic stem cell transplantation in pediatric solid tumors-A pediatric blood and marrow transplant consortium study.
    Ozkaynak MF; Sahdev I; Gross TG; Levine JE; Cheerva AC; Richards MK; Rozans MK; Shaw PJ; Kadota RP
    J Pediatr Hematol Oncol; 2008 Mar; 30(3):204-9. PubMed ID: 18376282
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
    van As JW; van den Berg H; van Dalen EC
    Cochrane Database Syst Rev; 2014 Jul; (7):CD009219. PubMed ID: 24984156
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Amifostine does not inhibit the toxic effects of anthracycline derivates or mitoxantrone on MDR tumor cell lines.
    Michieli M; Michelutti A; Damiani D; Ermacora A; Masolini P; Stocchi R; Russo D
    Leuk Lymphoma; 2001 Aug; 42(4):721-9. PubMed ID: 11697502
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amifostine: the preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies.
    Capizzi R
    Semin Oncol; 1996 Aug; 23(4 Suppl 8):2-17. PubMed ID: 8783661
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro effect of amifostine on haematopoietic progenitors exposed to carboplatin and non-alkylating antineoplastic drugs: haematoprotection acts as a drug-specific progenitor rescue.
    Pierelli L; Scambia G; Fattorossi A; Bonanno G; Battaglia A; Perillo A; Menichella G; Panici PB; Leone G; Mancuso S
    Br J Cancer; 1998 Oct; 78(8):1024-9. PubMed ID: 9792145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
    Capizzi RL
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):72-81. PubMed ID: 10348264
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Escalating sequential high-dose carboplatin and etoposide with autologous marrow support in children with relapsed solid tumors.
    Santana VM; Schell MJ; Williams R; Bowman LC; Thompson EI; Brenner MK; Mirro J
    Bone Marrow Transplant; 1992 Nov; 10(5):457-62. PubMed ID: 1464010
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemoprotection in anticancer therapy: the emerging role of amifostine (WR-2721).
    Kurbacher CM; Mallmann PK
    Anticancer Res; 1998; 18(3C):2203-10. PubMed ID: 9703784
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.